NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -1.3% · net new positions -4.5% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | -1 | 774.42K | $108.76M | n/a | −1 |
| Q2 2026 | 154 | 0 | 76.05M | $12.81B | +5 | −4 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 12.71M | -1.9% | $1.78B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (passive) | 9.71M | -1.0% | $1.36B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | JPMorgan Chase ✦ | 9.46M | n/a | $1.33B | 0.0% | n/c | 1 | SEC ↗ ×30 |
| 4 | Dodge & Cox ✦ | 5.56M | -0.2% | $780.04M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 4.35M | -2.7% | $610.16M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.87M | -7.1% | $402.43M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 2.77M | +83.7% | $388.44M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 8 | Renaissance Technologies ✦ | 2.42M | +2.2% | $339.48M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 2.02M | +3.4% | $283.50M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 1.83M | n/a | $256.47M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 11 | Wellington Management ✦ | 1.81M | -10.7% | $254.34M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 12 | Millennium Management ✦ | 977.21K | -18.2% | $137.18M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 793.24K | -61.3% | $111.35M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Goldman Sachs Group ✦ | 609.61K | n/a | $85.58M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | PRIMECAP Management ✦ | 512.26K | -2.2% | $71.91M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 411.66K | +228.9% | $57.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 347.56K | New | $48.79M | 0.1% | New | 1 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 136.35K | +49.6% | $19.14M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 97.29K | +133.6% | $13.66M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 20 | Fisher Asset Management ✦ | 94.80K | +8.3% | $13.31M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Fidelity (FMR) ✦ | 72.34K | -71.6% | $10.16M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 22 | Bridgewater Associates ✦ | 23.04K | +157.6% | $3.23M | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $48.79M | 0.1% |
Exited
| Norges Bank | $122.28M | was 0.0% |
| Adage Capital Partners | $42.93M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 690 holders, 94.09M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 826 sh · $130,051
Officer · 2.31K sh · $363,285
Officer · 2.15K sh · $333,030
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology